1
|
Abstract
Boron neutron capture therapy (BNCT) is a tumour selective particle radiotherapy, based on the administration of boron carriers incorporated preferentially by tumour cells, followed by irradiation with a thermal or epithermal neutron beam. BNCT clinical results to date show therapeutic efficacy, associated with an improvement in patient quality of life and prolonged survival. Translational research in adequate experimental models is necessary to optimise BNCT for different pathologies. This review recapitulates some examples of BNCT radiobiological studies for different pathologies and clinical scenarios, strategies to optimise boron targeting, enhance BNCT therapeutic effect and minimise radiotoxicity. It also describes the radiobiological mechanisms induced by BNCT, and the importance of the detection of biomarkers to monitor and predict the therapeutic efficacy and toxicity of BNCT alone or combined with other strategies. Besides, there is a brief comment on the introduction of accelerator-based neutron sources in BNCT. These sources would expand the clinical BNCT services to more patients, and would help to make BNCT a standard treatment modality for various types of cancer. Radiobiological BNCT studies have been of utmost importance to make progress in BNCT, being essential to design novel, safe and effective clinical BNCT protocols.
Collapse
|
2
|
Couto M, Alamón C, Nievas S, Perona M, Dagrosa MA, Teixidor F, Cabral P, Viñas C, Cerecetto H. Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer. Chemistry 2020; 26:14335-14340. [PMID: 32738078 DOI: 10.1002/chem.202002963] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 07/26/2020] [Indexed: 12/17/2022]
Abstract
About 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two-in-one hybrid systems should be implemented. Tyrosine kinase receptors-inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated-carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral- and BNCT-agents. One of the selected hybrids was studied against glioma-cells and found to be 4 times more cytotoxic than sunitinib and 1.7 times more effective than 10 B-boronophenylalanine fructose complex when the cells were irradiated with neutrons.
Collapse
Affiliation(s)
- Marcos Couto
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Catalina Alamón
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay
| | - Susana Nievas
- Department of Boron Neutron Capture Therapy, National Atomic Energy Commission (CNEA), Buenos Aires, Argentina
| | - Marina Perona
- Department of Radiobiology, CNEA, Buenos Aires, Argentina
| | | | - Francesc Teixidor
- Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Pablo Cabral
- Área de Radiofarmacia, Centro de Investigaciones Nucleares (CIN), Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Clara Viñas
- Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Hugo Cerecetto
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Área de Radiofarmacia, Centro de Investigaciones Nucleares (CIN), Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| |
Collapse
|
3
|
Couto M, Alamón C, García MF, Kovacs M, Trias E, Nievas S, Pozzi E, Curotto P, Thorp S, Dagrosa MA, Teixidor F, Viñas C, Cerecetto H. Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy. Cells 2020; 9:E1408. [PMID: 32517054 DOI: 10.3390/cells9061408] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 05/28/2020] [Accepted: 06/01/2020] [Indexed: 12/27/2022] Open
Abstract
One of the driving forces of carcinogenesis in humans is the aberrant activation of receptors; consequently, one of the most promising mechanisms for cancer treatment is receptor inhibition by chemotherapy. Although a variety of cancers are initially susceptible to chemotherapy, they eventually develop multi-drug resistance. Anti-tumor agents overcoming resistance and acting through two or more ways offer greater therapeutic benefits over single-mechanism entities. In this study, we report on a new family of bifunctional compounds that, offering the possibility of dual action (drug + radiotherapy combinations), may result in significant clinical benefits. This new family of compounds combines two fragments: the drug fragment is a lapatinib group, which inhibits the tyrosine kinase receptor activity, and an icosahedral boron cluster used as agents for neutron capture therapy (BNCT). The developed compounds were evaluated in vitro against different tyrosine kinase receptors (TKRs)-expressing tumoral cells, and in vitro–BNCT experiments were performed for two of the most promising hybrids, 19 and 22. We identified hybrid 19 with excellent selectivity to inhibit cell proliferation and ability to induce necrosis/apoptosis of glioblastoma U87 MG cell line. Furthermore, derivative 22, bearing a water-solubility-enhancing moiety, showed moderate inhibition of cell proliferation in both U87 MG and colorectal HT-29 cell lines. Additionally, the HT-29 cells accumulated adequate levels of boron after hybrids 19 and 22 incubations rendering, and after neutron irradiation, higher BNCT-effects than BPA. The attractive profile of developed hybrids makes them interesting agents for combined therapy.
Collapse
|
4
|
Ferrari E, Wittig A, Basilico F, Rossi R, De Palma A, Di Silvestre D, Sauerwein WA, Mauri PL. Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures. Molecules 2019; 24:molecules24040794. [PMID: 30813269 PMCID: PMC6412696 DOI: 10.3390/molecules24040794] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 02/15/2019] [Accepted: 02/19/2019] [Indexed: 12/19/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary cancer treatment modality where two different agents (10B and thermal neutrons) have to be present to produce an effect. A dedicated trial design is necessary for early clinical trials. The concentration of 10B in tissues is an accepted surrogate to predict BNCT effects on tissues. Tissue, blood, and urines were sampled after infusion of two different boron carriers, namely BSH and BPA in the frame of the European Organisation for Research and Treatment of Cancer (EORTC) trial 11001. In this study, urine samples were used to identify protein profiles prior and after drug infusion during surgery. Here, an approach that is based on the mass spectrometry (MS)-based proteomic analysis of urine samples from head and neck squamous cell carcinoma (HNSCC) and thyroid cancer patients is presented. This method allowed the identification of several inflammation- and cancer-related proteins, which could serve as tumor biomarkers. In addition, changes in the urinary proteome during and after therapeutic interventions were detected. In particular, a reduction of three proteins that were involved in inflammation has been observed: Galectin-3 Binding Protein, CD44, and osteopontin. The present work represents a proof of principle to follow proteasome changes during complex treatments based on urine samples.
Collapse
Affiliation(s)
- Emanuele Ferrari
- Proteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20090 Segrate (MI), Italy; (E.F.); (R.R.); (A.D.P.); (D.D.S.)
| | - Andrea Wittig
- Dept. of Radiotherapy and Radiation Oncology, University Hospital Jena, 07743 Jena, Germany;
| | - Fabrizio Basilico
- Proteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20090 Segrate (MI), Italy; (E.F.); (R.R.); (A.D.P.); (D.D.S.)
| | - Rossana Rossi
- Proteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20090 Segrate (MI), Italy; (E.F.); (R.R.); (A.D.P.); (D.D.S.)
| | - Antonella De Palma
- Proteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20090 Segrate (MI), Italy; (E.F.); (R.R.); (A.D.P.); (D.D.S.)
| | - Dario Di Silvestre
- Proteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20090 Segrate (MI), Italy; (E.F.); (R.R.); (A.D.P.); (D.D.S.)
| | | | - Pier Luigi Mauri
- Proteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20090 Segrate (MI), Italy; (E.F.); (R.R.); (A.D.P.); (D.D.S.)
- Istituto di Scienze della Vita, Scuola Superiore Sant’Anna, 56127 Pisa, Italy
- Correspondence: ; Tel.: +39-02-264226728
| |
Collapse
|
5
|
Rodriguez C, Carpano M, Curotto P, Thorp S, Casal M, Juvenal G, Pisarev M, Dagrosa MA. In vitro studies of DNA damage and repair mechanisms induced by BNCT in a poorly differentiated thyroid carcinoma cell line. Radiat Environ Biophys 2018; 57:143-152. [PMID: 29453554 DOI: 10.1007/s00411-017-0729-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 12/24/2017] [Indexed: 06/08/2023]
Abstract
Boron neutron capture therapy (BNCT) for aggressive tumors is based on nuclear reaction [10B (n, α) 7Li]. Previously, we demonstrated that BNCT could be applied for the treatment of undifferentiated thyroid carcinoma. The aim of the present study was to describe the DNA damage pattern and the repair pathways that are activated by BNCT in thyroid cells. We analyzed γH2AX foci and the expression of Ku70, Rad51 and Rad54, main effector enzymes of non-homologous end joining (NHEJ) and homologous recombination repair (HRR) pathways, respectively, in thyroid follicular carcinoma cells. The studied groups were: (1) C [no irradiation], (2) gamma [60Co source], (3) N [neutron beam alone], (4) BNCT [neutron beam plus 10 µg 10B/ml of boronphenylalanine (10BPA)]. The total absorbed dose was always 3 Gy. The results showed that the number of nuclear γH2AX foci was higher in the gamma group than in the N and BNCT groups (30 min-24 h) (p < 0.001). However, the focus size was significantly larger in BNCT compared to other groups (p < 0.01). The analysis of repair enzymes showed a significant increase in Rad51 and Rad54 mRNA at 4 and 6 h, respectively; in both N and BNCT groups and the expression of Ku70 did not show significant differences between groups. These findings are consistent with an activation of HRR mechanism in thyroid cells. A melanoma cell line showed different DNA damage pattern and activation of both repair pathways. These results will allow us to evaluate different blocking points, to potentiate the damage induced by BNCT.
Collapse
Affiliation(s)
- C Rodriguez
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
| | - M Carpano
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
| | - P Curotto
- RA-3-Investigation and Production Reactors (CAE, CNEA), 15 Presbítero González y Aragón Rd, Buenos Aires, Argentina
| | - S Thorp
- Instrumentation and Control Department (CAE, CNEA), 15 Presbítero González y Aragón Rd, Buenos Aires, Argentina
| | - M Casal
- Oncology Institute "Ángel H. Roffo"-University of Buenos Aires, 5481 San Martín Av, Ciudad Autónoma de Buenos Aires, Argentina
| | - G Juvenal
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
- Scientific and Technical Research National Council (CONICET), 1917 Rivadavia St, Ciudad Autónoma de Buenos Aires, Argentina
| | - M Pisarev
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
- Scientific and Technical Research National Council (CONICET), 1917 Rivadavia St, Ciudad Autónoma de Buenos Aires, Argentina
| | - M A Dagrosa
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina.
- Scientific and Technical Research National Council (CONICET), 1917 Rivadavia St, Ciudad Autónoma de Buenos Aires, Argentina.
| |
Collapse
|
6
|
Roda E, Nion S, Bernocchi G, Coccini T. Blood–brain barrier (BBB) toxicity and permeability assessment after L-(4-10Boronophenyl)alanine, a conventional B-containing drug for boron neutron capture therapy, using an in vitro BBB model. Brain Res 2014; 1583:34-44. [DOI: 10.1016/j.brainres.2014.08.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 08/07/2014] [Indexed: 12/24/2022]
|
7
|
De Simone U, Manzo L, Ferrari C, Bakeine J, Locatelli C, Coccini T. Short and long-term exposure of CNS cell lines to BPA-f a radiosensitizer for Boron Neutron Capture Therapy: safety dose evaluation by a battery of cytotoxicity tests. Neurotoxicology 2013; 35:84-90. [DOI: 10.1016/j.neuro.2012.12.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2012] [Revised: 12/13/2012] [Accepted: 12/14/2012] [Indexed: 12/21/2022]
|